共 264 条
[1]
de Lau LM(2006)Epidemiology of Parkinson’s disease Lancet Neurol Elsevier 5 525-535
[2]
Breteler MM(2014)Pharmacological treatment of Parkinson disease JAMA. 311 1670-708
[3]
Connolly BS(2012)Cognitive impairment and dementia in Parkinson’s disease: clinical features, diagnosis, and management Front Neurol 3 88-437
[4]
Lang AE(2016)Cerebral metabolic differences associated with cognitive impairment in Parkinson’s disease PLoS One 11 e0152716-647
[5]
Meireles J(2013)Cognitive change in newly-diagnosed patients with Parkinson’s disease: a 5-year follow-up study J Int Neuropsychol Soc 19 695-1614
[6]
Massano J(2009)Cognitive decline in Parkinson’s disease: a prospective longitudinal study J Int Neuropsychol Soc 15 426-1142
[7]
Tang Y(2007)Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models Nature. 445 643-6907
[8]
Ge J(2003)Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias Eur J Neurosci 18 1607-620.e8
[9]
Liu F(2005)A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease FASEB J 19 1140-389
[10]
Wu P(2002)Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission J Neurosci 22 6900-1142